Skip to main content

ASCIA News

  • ASCIA 2025 Conference registration and abstract submission
    The ASCIA 2025 Conference is being held from Tuesday 2 to Friday 5 September 2025 at the Brisbane Convention and Exhibition Centre. This is a hybrid conference, which enables virtual registration for delegates who cannot attend in-person. On-demand viewing of recorded...
  • National Allergy Priorities for Research
    The National Allergy Centre of Excellence is Setting National Allergy Priorities for Research (SNAPR), to help make sure future allergy research addresses the issues that matter most to people living with allergies, their families and healthcare providers.   What's involved? Complete the...
  • EOIs for 2025 AIFA grant round are due 30 May   
    It is a pleasure to announce that Expressions of Interest (EOIs) are invited from ASCIA members for AIFA grants that support clinically important research into allergy and other immune diseases. EOIs are due by midnight on 30 May 2025 and the form is on the AIFA website...
  • ASCIA Immunodeficiency Strategy - April 2025 update
    To coincide with World PI Week (22 - 29 April 2025) and World Immunology Day on 29 April 2025, ASCIA is proud to announce that a new ASCIA Project Officer, Vargha Khosh Aein, has been appointed, to progress implementation of the ASCIA Immunodeficiency Strategy for...
  • New international consensus report on anaphylaxis
    A new international consensus report on anaphylaxis has been released by the Global Allergy and Asthma Excellence Network (GA2LEN) and published open access online in the Journal of Allergy and Clinical Immunology.  The report was developed by an international panel of 46...
  • FASENRA (benralizumab) approved for eosinophilic granulomatosis with polyangiitis (EGPA)
    This news item was issued on 8 April 2025 by Jill Smith, CEO of ASCIA, the peak professional body for clinical immunology and allergy in Australia and New Zealand.   ASCIA Members please log in to view.
  • ALBEY venom immunotherapy available from April 2025
    This news item was issued on 8 April 2025 by Jill Smith, CEO of ASCIA, the peak professional body for clinical immunology and allergy in Australia and New Zealand.  ASCIA Members please log in to view.
  • ALUSTAL allergen immunotherapy available from April 2025
    This news item was issued on 8 April 2025 by Jill Smith, CEO of ASCIA, the peak professional body for clinical immunology and allergy in Australia and New Zealand.  ASCIA Members please log in to view.
ASCIA Member Login

Site last updated: 14 May 2025
 

ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.

Join our mailing list or see latest edition here...